133409-91-3

Upstream product

• 139191-95-0 3-Difluoromethyl-4-methyl-phenol 
• 34265-55-9 ethyl 3-hydroxy-6-methylbenzoate 
• 133409-96-8 1-tert-Butoxycarbonyloxy-3-difluoromethyl-4-methylbenzene 
• 133409-97-9 2-(Benzhydrylidene-amino)-3-(4-tert-butoxycarbonyloxy-2-difluoromethyl-phenyl)-propionic acid ethyl ester 
• 139191-90-5 1-(4-Methoxybenzyloxy)-3-carboethoxy-4-methylbenzene 
• 133409-98-0 1-(4-Methoxybenzyloxy)-3-difluoromethyl-4-methylbenzene 
• 139191-91-6 1-(4-Methoxybenzyloxy)-3-hydroxymethyl-4-methylbenzene 
• 139191-92-7 1-tert-Butoxycarbonyloxy-3-difluoromethyl-4-bromomethyl Benzene 
• 133409-95-7 1-(4-Methoxybenzyloxy)-3-formyl-4-methylbenzene 

Relevant academic research and scientific papers

Syntheses ofDL-2-fluoromethy-P-tyrosine andDL-2-difluoromethyl-P-tyrosine as potential inhibitors of tyrosine hydroxylase

The syntheses of the title compounds from 3,4-dimethylanisole and ethyl 5-hydroxy-2-methylbenzoate, respectively, are described.

Pharmaceutically active fluoromethyltyrosine compounds

This invention relates to novel monofluoromethyl- and difluoromethyltyrosine compounds which are active as tyrosine hydroxylase inhibitors and are therefore useful in the treatment of conditions caused by high levels of catecholamines such as hypertension